Relationship Graph Explorer

Follow the connections

Every herb, ingredient, formula, gene target, and disease — connected through real research. Search, pick a subject, and navigate the graph in any direction.

🌿

Herb

→

→

→

→

🧪

Evidence

23,295

trials · metas · refs

Plus 6,743 TCM formulas connecting herbs together

Subject Type: 🌿 Herbs ⚗️ Ingredients 📜 Formulas 🧬 Targets 🏥 Diseases

Quick picks: Taxol Oxytocin Morphine (?)-nicotine Testosterone Melatonin Caffeine L-ascorbic acid Progesterone Coumarins

⚗️ Ingredient

Anhydroicaritin

Open on HERB 2.0 ↗

Clinical Trials

Meta-Analyses

PubMed References

Top Conditions Studied with Anhydroicaritin

Hepatocellular Carcinoma (HCC) 2 Advanced HBV-Related Hepatocellular Carcinoma (HCC) 1 Solid Tumors 1

📋 Sample Trials

NCT01972672

The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

Completed · Phase 2

NCT03236636

The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Unknown · Phase 3

NCT03236649

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Terminated · Phase 3

📊 Sample Meta-Analyses

None linked yet.

📚 Sample References

PMID 33354776

Icaritin inhibits PD-L1 expression by Targeting Protein IκB Kinase α

Eur J Immunol · 2021

PMID 33417961

Icaritin ameliorates hepatic steatosis via promoting fatty acid β-oxidation and insulin sensitivity

Life Sci · 2021

PMID 33805302

Icaritin Provides Neuroprotection in Parkinson's Disease by Attenuating Neuroinflammation, Oxidative Stress, and Energy Deficiency

Antioxidants (Basel) · 2021

⚗️ All Ingredient data fields for Anhydroicaritin

⚗️ Identity

Name

Anhydroicaritin

Aliases / Synonyms

Icaritin; beta-Anhydroicaritin; 3,5-dihydroxy-2-(4-methoxyphenyl)-8,8-dimethyl-9,10-dihydropyrano[2,3-h]chromen-4-one; CHEMBL497654; ?-anhydroicaritin; 3,5-dihydroxy-2-(4-methoxyphenyl)-8,8-dimethyl-9,10-dihydropyrano(2,3-h)chromen-4-one; I(2)-Anhydroicaritin; SCHEMBL4220888; DTXSID801316333

🧪 Chemistry

Molecular Weight

368.3850

LogP

3.9834

Drug-likeness

0.711

Oral Bioavailability

45.4120

H-Bond Acceptors

H-Bond Donors

Rotatable Bonds

🔬 Structures

Canonical SMILES

CC1(CCC2=C(O1)C=C(C3=C2OC(=C(C3=O)O)C4=CC=C(C=C4)OC)O)C

Isomeric SMILES

CC1(CCC2=C(O1)C=C(C3=C2OC(=C(C3=O)O)C4=CC=C(C=C4)OC)O)C

InChIKey

PPCHTBBOSVKORE-UHFFFAOYSA-N

InChI

InChI=1S/C21H20O6/c1-21(2)9-8-13-15(27-21)10-14(22)16-17(23)18(24)19(26-20(13)16)11-4-6-12(25-3)7-5-11/h4-7,10,22,24H,8-9H2,1-3H3

🔗 External References

HERB DB

HBIN016163 ↗

PubChem CID

14583584 ↗

CAS Number

118525-40-9 ↗

NPASS

NPC273538

HIT

C0137

SymMap

6301

TCMID

1273; 33248

TCMSP

MOL004373; MOL004393

TCM-ID

10719

🔍 Raw view — every non-empty column on this row (34 fields)

name

Anhydroicaritin

common names

herb ingredient id

HBIN016163

canonical smiles

CC1(CCC2=C(O1)C=C(C3=C2OC(=C(C3=O)O)C4=CC=C(C=C4)OC)O)C

isomeric smiles

CC1(CCC2=C(O1)C=C(C3=C2OC(=C(C3=O)O)C4=CC=C(C=C4)OC)O)C

inchi

InChI=1S/C21H20O6/c1-21(2)9-8-13-15(27-21)10-14(22)16-17(23)18(24)19(26-20(13)16)11-4-6-12(25-3)7-5-11/h4-7,10,22,24H,8-9H2,1-3H3

inchikey

PPCHTBBOSVKORE-UHFFFAOYSA-N

mol wt

368.3850

num h acceptors

num h donors

mol logp

3.9834

num rotatable bonds

drug likeness

0.711

ob score

45.4120

cas id

118525-40-9

symmap mol id

6301

tcmid ingredient id

1273; 33248

tcmsp ingredient id

MOL004373; MOL004393

tcm id ingredient id

10719

pubchem cid

14583584

npass id

NPC273538

hit id

C0137

🏥 Linked Health Topics

2 · diseases via target pathways

Solid tumors

disease

Hepatocellular Carcinoma (HCC)

disease

📋 Clinical Trials

4 · subject of clinical study

NCT01972672 The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinom

→ Hepatocellular Carcinoma (HCC)

NCT03236636 The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinom

→ Advanced HBV-Related Hepatocellular Carcinoma (HCC

NCT03236649 The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepa

→ Hepatocellular Carcinoma (HCC)

NCT02496949 A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Soli

→ Solid Tumors

📚 PubMed References

10 · cited research

PMID 33354776 Icaritin inhibits PD-L1 expression by Targeting Protein IκB Kinase α

Eur J Immunol

PMID 33417961 Icaritin ameliorates hepatic steatosis via promoting fatty acid β-oxidation and

Life Sci

PMID 33805302 Icaritin Provides Neuroprotection in Parkinson's Disease by Attenuating Neuroinf

Antioxidants (Basel)

PMID 35026517 Icaritin inhibited cigarette smoke extract-induced CD8+ T cell chemotaxis enhanc

Phytomedicine

PMID 35257426 Icaritin ameliorates extracellular microparticles-induced inflammatory pre-metas

Phytother Res

PMID 35433438 Icaritin Inhibits Migration and Invasion of Human Ovarian Cancer Cells via the A

Front Oncol

PMID 35489659 Identifying the anti-metastasis effect of Anhydroicaritin on breast cancer: Coup

J Ethnopharmacol

PMID 35663228 Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and

Mol Ther Oncolytics

PMID 36447154 Icaritin inhibits neuroinflammation in a rat cerebral ischemia model by regulati

Mol Med

PMID 36467051 Exploring the pharmacological mechanisms of icaritin against nasopharyngeal carc

Front Pharmacol

How relationships are computed

Clinical Trials / Meta-Analyses / References: direct foreign-key link via subject_entity_id (Phase 2d wireup)
Formula ↔ Herbs: text bridge via formulas.herbs_in_pinyin matching herbs.pinyin_name
Herb ↔ Ingredient: ACTIVE — direct link via herb_ingredients
Ingredient ↔ Target: ACTIVE — direct link via ingredient_targets
Target ↔ Disease: ACTIVE — direct link via target_health_topics
Herb → Target → Disease (full chemical spine): ACTIVE — joins all three link tables